Compare GMED & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMED | CYTK |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.7B |
| IPO Year | 2012 | 2004 |
| Metric | GMED | CYTK |
|---|---|---|
| Price | $83.19 | $72.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | ★ $100.42 | $89.26 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 422.67 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $2,938,931,000.00 | $13,368,000.00 |
| Revenue This Year | $11.13 | $7.37 |
| Revenue Next Year | $6.28 | $310.19 |
| P/E Ratio | $41.27 | ★ N/A |
| Revenue Growth | ★ 16.65 | N/A |
| 52 Week Low | $54.17 | $44.93 |
| 52 Week High | $101.40 | $88.31 |
| Indicator | GMED | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 40.68 |
| Support Level | $82.01 | $73.34 |
| Resistance Level | $82.23 | $79.66 |
| Average True Range (ATR) | 2.06 | 2.14 |
| MACD | -0.56 | 0.07 |
| Stochastic Oscillator | 5.54 | 27.81 |
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.